Search
forLearn
5 / 801 resultslearn Kopexil
learn Setipiprant
learn Tofacitinib
a JAK inhibitor for alopecia areata and other autoimmune conditions
learn Naltrexone
Research
5 / 1000+ results
research Plerixafor Biases CXCR4 Signaling Through β-Arrestin to Promote Melanogenesis via β-Catenin–MITF Activation
Plerixafor may help treat pigmentation disorders by promoting skin repigmentation.
research Pharmacological Mobilization of Endogenous Stem Cells Significantly Promotes Skin Regeneration after Full-Thickness Excision: The Synergistic Activity of AMD3100 and Tacrolimus
Using the drugs AMD3100 and Tacrolimus together greatly improves skin healing and hair growth after a deep skin cut by increasing stem cells in the wound.
research 639-P: Pharmacological Mobilization and Recruitment of Bone Marrow Stem Cells Accelerates Diabetic Wound Healing in Rats with Diabetic Complications
Using a combination of AMD3100 and FK506 can speed up and improve wound healing in diabetic rats.
research Single-cell analysis of murine fibroblasts identifies neonatal to adult switching that regulates cardiomyocyte maturation
Adult fibroblasts help heart cells mature and improve heart function.
research Stem cells in tissues, organoids, and cancers
Stem cells are crucial for tissue growth, cancer treatment, and disease modeling, but challenges remain in clinical use.
Community Join
5 / 1000+ resultscommunity Pirfenidone - The answer to fibrosis and baldness
Pirfenidone is suggested to treat fibrosis and baldness by blocking inflammation markers and reducing collagen. It is also available as a gel for scar removal.
community The story of RU58841/PSK3841
RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.
community Kintor KX -826 Pyrilutamide Adds 1 Year Phase 3 Trial For Safety
KX-826/pyrilutamide is undergoing an additional one-year safety and efficacy trial in China after a six-month study. Some participants speculate on the reasons for the extended trial and discuss the potential of other treatments.
community Pyrilutamide / KX-826 | Discussion EU
The conversation is about a user expressing concerns over the safety of a new drug called Pyrilutamide (also known as KX-826) for hair loss. The user will only trust the drug if it's permitted by EU regulations and sold by a reputable company.
community KX-826 Pyrilutamide1% coming soon
KX-826 Pyrilutamide 1% is launching soon, and users are discussing its potential benefits and drawbacks compared to other treatments like Minoxidil and finasteride. Some users are skeptical about its effectiveness, while others are hopeful it will be a safer alternative.